by Ethan Webb | Jul 21, 2026 | Regulation
New trial data on GLP-1 drugs and alcohol use disorder is the strongest yet, but semaglutide remains unapproved for addiction and the questions for providers are only starting. Key Takeaways The signal is getting harder to dismiss. A 2026 randomized trial found...
